IMPAX LABORATORIES INC (IPXL) Stock News
NASDAQ:IPXL - Nasdaq - US45256B1017
IPXL Latest News, Press Relases and Analysis
AiViva's Diverse Product Pipeline Could Have The Potential To Transform Unmet Medical Needs
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases.
TNN | Recent Fundamentals: Impax Laboratories (NASDAQ: IPXL)
Margin of Safety Calculated for NASDAQ:IPXL | Industrials, News
There’s a shortage of U.S. EpiPens and other allergic reaction treatments, advocacy group says
More than 400 people in 45 states surveyed by the group said they had trouble filling or refilling their prescriptions
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
Mentions: ANIP
Amneal and Impax Complete Business Combination
Mentions: AMRX
Blog Exposure - Impax Launched a Generic Version of Estrace(R) Cream
Mentions: RMTI
Apergy Set to Join S&P MidCap 400; 3D Systems to Join S&P SmallCap 600
Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader
Impax Laboratories Inc (NASDAQ: IPXL) announced an agreement in October to merge with privately held Amneal Pharma, with 75 percent of the combined company held by Amneal...
Impax Laboratories, Inc. (IPXL): Resumes Bullish Coverage
IPXL – Barclays resumes coverage as an overweight, $27PT. This price target represents a 43.62% upside over the stock’s previous closing price of $18.80.
Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress(TM)
Mentions: ASMB
Stocks To Trade: SQ, IPXL, ALSN
Thursday's stock picks: Square, Impax Laboratories and Allison Transmission.
Analysts Conflicted on These Healthcare Names: Achaogen (NASDAQ: AKAO), Cytori Therap (NASDAQ: CYTX) and Impax Laboratories (NASDAQ: IPXL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ...
The post Analysts Conflicted on These Healthcare Names: Achaogen (NASDAQ: AKAO), Cytori Therap (NASDAQ: CYTX) and Impax Laboratories (NASDAQ: IPXL) appeared first on Smarter Analyst.
Analysts Conflicted on These Healthcare Names: Achaogen (NASDAQ: AKAO), Cytori Therap (NASDAQ: CYTX) and Impax Laboratories (NASDAQ: IPXL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Achaogen (NASDAQ: AKAO), Cytori Therap (NASDAQ: CYTX) and Impax Laboratories (NASDAQ: IPXL). Achaogen (NASDAQ: AKAO) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Achaogen (NASDAQ: AKAO) today and set a price target of $29. The company’s shares opened
The post Analysts Conflicted on These Healthcare Names: Achaogen (NASDAQ: AKAO), Cytori Therap (NASDAQ: CYTX) and Impax Laboratories (NASDAQ: IPXL) appeared first on Analyst Ratings.
Amneal And Impax Receive FTC Clearance For Business Combination
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax
Mentions: ANIP
Impax Laboratories, Inc. (IPXL): PT Raised News
IPXL – BMO Capital raises PT to $20 from $18. This new price target represents a 8.99% upside over the stock’s previous closing price of $18.35.
Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%)
Mentions: PRGO
Impax Shareholders Approve Proposed Business Combination with Amneal
Amneal Gains Approval for Erythromycin Tablets USP
Amneal Pharmaceuticals and Impax Laboratories to Present at the Barclays Global Healthcare Conference
Impax Laboratories, Inc. (IPXL): New Bullish Coverage
IPXL – SunTrust Robinson Humphrey initiates as a buy, $24PT. This price target represents a 26.32% upside over the stock’s previous closing price of $19.00.
Impax Laboratories, Inc. (IPXL): Bullish PT Set
IPXL – Cantor Fitzgerald sets PT at $35. Stock price at the time of this analyst call was $20.40.
Amneal Launches Generic for Tamiflu® Oral Suspension
Impax Reports Fourth Quarter and Full Year 2017 Results
You still can’t buy this EpiPen competitor, eight months later
Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.
Analysts Offer Insights on Healthcare Companies: Aimmune Therapeutics (NASDAQ: AIMT), Galapagos NV (NASDAQ: GLPG) and Impax Laboratories (NASDAQ: IPXL)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aimmune Therapeutics (NASDAQ: AIMT), Galapagos NV (NASDAQ: GLPG) and Impax Laboratories (NASDAQ: IPXL). Aimmune Therapeutics (NASDAQ: AIMT) Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT) today and set a price target of $72.
The post Analysts Offer Insights on Healthcare Companies: Aimmune Therapeutics (NASDAQ: AIMT), Galapagos NV (NASDAQ: GLPG) and Impax Laboratories (NASDAQ: IPXL) appeared first on Analyst Ratings.
Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®
Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations
Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®
Amneal Introduces Isotretinoin Capsules, USP
Impax Laboratories, Inc. (IPXL): Corp. News News
IPXL – Impax Labs subsidiary CorePharma acquired by Investor Group; Details not disclosed.
CorePharma, LLC Acquired by Investor Group
Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream
Mentions: PRGO